DDInter1008 DDInter582
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013. On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca.
Ketoconazole {u} (Compound) causes {v} (Side Effect) Insomnia
Insomnia {u} (Side Effect) is caused by {v} (Compound) Dolutegravir
Ketoconazole {u} (Compound) causes {v} (Side Effect) Insomnia
Insomnia {u} (Side Effect) is caused by {v} (Compound) Griseofulvin
Griseofulvin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Ketoconazole {u} (Compound) downregulates {v} (Gene) PPP2R3C
PPP2R3C {u} (Gene) is regulated by {v} (Gene) UGT1A1
UGT1A1 {u} (Gene) is bound by {v} (Compound) Dolutegravir
Ketoconazole {u} (Compound) binds {v} (Gene) AR
AR {u} (Gene) interacts with {v} (Gene) POU2F2
POU2F2 {u} (Gene) is bound by {v} (Compound) Dolutegravir
Ketoconazole {u} (Compound) downregulates {v} (Gene) PPP2R3C
PPP2R3C {u} (Gene) is downregulated by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Ketoconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Itraconazole {u} (Compound) causes {v} (Side Effect) Insomnia
Insomnia {u} (Side Effect) is caused by {v} (Compound) Dolutegravir
Ketoconazole {u} (Compound) binds {v} (Gene) AR
AR {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Ketoconazole {u} (Compound) downregulates {v} (Gene) PPP2R3C
PPP2R3C {u} (Gene) is downregulated by {v} (Compound) Orlistat
Orlistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dolutegravir
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} (Compound) causes {v} (Side Effect) Insomnia
Insomnia {u} (Side Effect) is caused by {v} (Compound) Dolutegravir
Ketoconazole {u} (Compound) causes {v} (Side Effect) Abdominal pain upper
Abdominal pain upper {u} (Side Effect) is caused by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dolutegravir
Ketoconazole (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dolutegravir (Compound)
Ketoconazole (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Griseofulvin (Compound) and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Ketoconazole (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is regulated by UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Dolutegravir (Compound)
Ketoconazole (Compound) binds AR (Gene) and AR (Gene) interacts with POU2F2 (Gene) and POU2F2 (Gene) is bound by Dolutegravir (Compound)
Ketoconazole (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is downregulated by Chloramphenicol (Compound) and Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Ketoconazole (Compound) resembles Itraconazole (Compound) and Itraconazole (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dolutegravir (Compound)
Ketoconazole (Compound) binds AR (Gene) and AR (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Ketoconazole (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is downregulated by Orlistat (Compound) and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Dolutegravir
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dolutegravir (Compound)
Ketoconazole (Compound) causes Abdominal pain upper (Side Effect) and Abdominal pain upper (Side Effect) is caused by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Dolutegravir